Osteosarcoma: The same old drugs or more?

被引：55

作者：

Bielack, Stefan S. ^{[1
,2
]}

Marina, Neyssa ^{[3
,4
]}

Ferrari, Stefano ^{[5
]}

Helman, Lee J. ^{[6
]}

Smeland, Sigbjorn ^{[7
]}

Whelan, Jeremy S. ^{[8
]}

Reaman, Gregory H. ^{[9
]}

机构：

[1] Olga Hosp, Klinikum Stuttgart, Stuttgart, Germany

[2] Univ Klinikum Munster, Munster, Germany

[3] Stanford Univ, Med Ctr, Div Hematol Oncol, Palo Alto, CA 94304 USA

[4] Lucile Packard Childrens Hosp, Palo Alto, CA 94304 USA

[5] Ist Ortoped Rizzoli, Sez Chemioterapia, Bologna, Italy

[6] NIH, Ctr Canc Res, Bethesda, MD 20892 USA

[7] Rikshosp Univ Hosp, Norwegian Radium Hosp, Div Canc Med & Radiotherapy, Oslo, Norway

[8] UCL Hosp, Dept Oncol, London, England

[9] George Washington Univ, Childrens Natl Med Ctr, Div Oncol, Washington, DC USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 18期

关键词：

D O I：

10.1200/JCO.2008.17.1108

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：3102 / 3103

页数：2

共 9 条

[1] Delaying surgery with chemotherapy for osteosarcoma of the extremities [J].

Bielack, SS ;

Machatschek, JN ;

Flege, S ;

Jürgens, H .

EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (06) :1243-1256

[2] ADJUVANT CHEMOTHERAPY IN OSTEOGENIC-SARCOMA - THE TRIUMPH THAT ISNT [J].

CARTER, SK .

JOURNAL OF CLINICAL ONCOLOGY, 1984, 2 (03) :147-148

[3] Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival [J].

Ferrari, S ;

Briccoli, A ;

Mercuri, M ;

Bertoni, F ;

Picci, P ;

Tienghi, A ;

Del Prever, AB ;

Fagioli, F ;

Comandone, A ;

Bacci, G .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :710-715

[4] ADJUVANT CHEMOTHERAPY OF OSTEOSARCOMA - NO RUNS, NO HITS, 2 MEN LEFT ON BASE [J].

HOLLAND, JF .

JOURNAL OF CLINICAL ONCOLOGY, 1987, 5 (01) :4-6

[5]

JAFFE N, 1983, CANC TREAT REP, V67, P1743

[6] Osteosarcoma relapse after combined modality therapy:: An analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS) [J].

Kempf-Bielack, B ;

Bielack, SS ;

Jürgens, H ;

Branscheid, D ;

Berdel, WE ;

Exner, GU ;

Göbel, U ;

Helmke, K ;

Jundt, G ;

Kabisch, H ;

Kevric, M ;

Klingebiel, T ;

Kotz, R ;

Maas, R ;

Schwarz, R ;

Semik, M ;

Treuner, J ;

Zoubek, A ;

Winkler, K .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (03) :559-568

[7]

LANGE B, 1982, CANCER TREAT REP, V66, P1699

[8] Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate [J].

Meyers, PA ;

Schwartz, CL ;

Krailo, M ;

Kleinerman, ES ;

Betcher, D ;

Bernstein, ML ;

Conrad, E ;

Ferguson, W ;

Gebhardt, M ;

Goorin, AM ;

Harris, MB ;

Healey, J ;

Huvos, A ;

Link, M ;

Montebello, J ;

Nadel, H ;

Nieder, M ;

Sato, J ;

Siegal, G ;

Weiner, M ;

Wells, R ;

Wold, L ;

Womer, R ;

Grier, H .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :2004-2011

[9] Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group [J].

Meyers, Paul A. ;

Schwartz, Cindy L. ;

Krailo, Mark D. ;

Healey, John H. ;

Bernstein, Mark L. ;

Betcher, Donna ;

Ferguson, William S. ;

Gebhardt, Mark C. ;

Goorin, Allen M. ;

Harris, Michael ;

Kleinerman, Eugenie ;

Link, Michael P. ;

Nadel, Helen ;

Nieder, Michael ;

Siegal, Gene P. ;

Weiner, Michael A. ;

Wells, Robert J. ;

Womer, Richard B. ;

Grier, Holcombe E. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) :633-638

← 1 →